Aptinyx Inc. (NASDAQ:APTX – Get a rating) – Truist Financial raised its second-quarter 2022 earnings estimate for Aptinyx shares in a note to investors on Thursday, April 7. Truist Financial analyst J. Lee now expects the company to post earnings per share of ($0.30) for the quarter, up from his previous estimate of ($0.31). Truist Financial has a “Buy” rating and a price target of $5.00 on the stock. Truist Financial also released Aptinyx Q3 2022 earnings estimates at ($0.23) EPS, Q4 2022 earnings at ($0.26) EPS, FY2022 earnings at ($1. $0.8) EPS and FY2023 earnings at ($0.79) EPS.
Several other research analysts have also recently weighed in on APTX. William Blair upgraded Aptinyx from an “outperforming” rating to a “market performing” rating in a Thursday, April 7 research note. BMO Capital Markets cut its price target on Aptinyx from $12.00 to $6.00 in a research note on Friday. Zacks Investment Research upgraded Aptinyx from a “buy” rating to a “hold” rating in a Friday, March 25 research note. SVB Leerink reduced its price target on Aptinyx from $12.00 to $10.00 and set an “outperform” rating for the company in a Monday, Dec. 20 research note. Finally, Cantor Fitzgerald cut his price target on Aptinyx from $11.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday. Two research analysts rated the stock with a hold rating and three gave the company a buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $5.80.
Aptinyx Stock opened at $1.19 on Monday. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt ratio of 0.15. The company’s fifty-day simple moving average is $2.91 and its two-hundred-day simple moving average is $2.66. Aptinyx has a 12-month low of $1.14 and a 12-month high of $4.73. The company has a market capitalization of $80.58 million, a price-earnings ratio of -1.07 and a beta of 1.09.
Aptyx (NASDAQ:APTX – Get a rating) last reported results on Wednesday, March 23. The company reported ($0.29) EPS for the quarter, beating Thomson Reuters consensus estimate of ($0.35) by $0.06. In the same period of the previous year, the company had earned earnings per share of ($0.20).
In other news, Director Joan W. Miller acquired 17,700 Aptinyx shares in a transaction that took place on Thursday, January 13. The stock was purchased at an average price of $2.83 per share, for a total transaction of $50,091.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. 7.94% of the shares are currently held by company insiders.
Institutional investors have recently been buying and selling shares of the stock. Royal Bank of Canada increased its position in Aptinyx by 244.5% during the second quarter. Royal Bank of Canada now owns 9,288 shares of the company valued at $26,000 after acquiring an additional 6,592 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in Aptinyx in the fourth quarter worth approximately $29,000. Blair William & Co. IL purchased a new stake in Aptinyx in the fourth quarter worth approximately $51,000. Lindbrook Capital LLC purchased a new stake in Aptinyx in the fourth quarter worth approximately $53,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Aptinyx in the fourth quarter worth approximately $54,000. Institutional investors hold 50.34% of the company’s shares.
Aptinyx Company Profile (Get a rating)
Aptinyx Inc is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458 and AGN-241751 program. The company was founded by Norbert G.
Get news and reviews for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Aptinyx and related companies with MarketBeat.com’s free daily email newsletter.